Recognizing that neoplasm cells can hijack immune checkpoint pathways like cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed death-1 (PD-1) to evade the immune system, immune checkpoint blockade therapy was developed as a novel immunotherapeutic approach [142]. Here, CTLA4 is linked to neoplasm.